Daily Patient’s Relief From Pruritus and Sleep Disturbance Over One-Month Treatment with Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Multicenter Prospective Study
Restricted accessLetterFirst published online September, 2025
Daily Patient’s Relief From Pruritus and Sleep Disturbance Over One-Month Treatment with Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Multicenter Prospective Study
AugustinM, LangenbruchA, BlomeC, et al.Characterizing treatment-related patient needs in atopic eczema: Insights for personalized goal orientation. J Eur Acad Dermatol Venereol. 2020; 34(1):142–152.
2.
TancrediV, LicataG, CalabreseG, et al.Is itching in atopic dermatitis still an unmet need? A case series of 556 patients. J Eur Acad Dermatol Venereol. 2022; 36(8):e650–e652.
3.
Guttman-YasskyE, TeixeiraHD, SimpsonEL, et al.Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): Results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021; 397(10290):2151–2168.
4.
SimpsonEL, PrajapatiVH, LeshemYA, et al.Upadacitinib rapidly improves patient-reported outcomes in atopic dermatitis: 16-week results from phase 3 clinical trials (measure up 1 and 2). Dermatol Ther (Heidelb). 2024; 14(5):1127–1144.
5.
SilverbergJI, GooderhamM, KatohN, et al.Combining treat-to-target principles and shared decision-making: International expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024; doi: 10.1111/dv.20229
